The last trial in TBI, the highly fancied application of progesterone to treat acute brain injury, was stopped because of futility. To date, more than 30 clinical trials have investigated a range of compounds for the treatment of severe TBI yet no drug has been approved. If Trofinetide succeeds it will be in no small part due to the drugs effect in inhibiting inflammation.
Chronic inflammation is a feature of the underlying pathology of many - if not all - neurodegenerative and neurodevelopmental diseases and conditions. In fact there is an interesting causal connection between TBI and Alzheimers Disease. Serious head injuries is a known risk factor for AD. In fact the spotlight is increasingly being shone upon inflammation as a trigger for AD rather than a response to damaging amyloid plaques.
Will the medical history books be re-written following the conclusion of the Intrepid-2566 trial? If so, attention could quickly focus upon the application of Trofinetide to treat a range of diseases and conditions - whether it is the complete answer or a partial answer in addressing the role of immune-mediated actions in the pathogenesis of disease within the brain.
NEU Price at posting:
9.6¢ Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)